Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

4SC 208

Next Previous
Drug Profile

4SC 208

Alternative Names: 4SC-208

Latest Information Update: 03 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 4SC
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Hedgehog cell signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 03 Oct 2023 Discontinued - Preclinical for Cancer in Germany (unspecified route) (4SC pipeline, October 2023)
  • 28 Feb 2021 No recent reports of development identified for preclinical development in Cancer in Germany
  • 22 Jan 2018 4SC receives patent allowance for the composition of matter of a group of molecules including 4SC 208 in China, Japan, Singapore, Australia and New Zealand

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top